Weight-loss supplement review
This article was originally published in The Tan Sheet
Executive Summary
Chitosan and chromium picolinate show a "relative paucity of compelling evidence to suggest the effectiveness of dietary supplements in weight loss," Max Pittler and Edzard Ernst, Universities of Exeter and Plymouth, UK, report in April American Journal of Clinical Nutrition. The researchers' literature search for supplements touted for weight loss turned up "five systematic reviews and meta-analyses based on the results of double-blind [randomized clinical trials] and 25 additional double-blind RCTs." Pittler and Ernst looked at 12 ingredients in all. Despite finding some "encouraging" results, investigators called the overall evidence unconvincing...
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.